The Utility of Portable Dual-Energy X-Ray Absorptiometry of the Wrist in Patients Referred to a Bone Health Clinic: A Pilot Study

Fifty white female patients referred to a bone health care clinic were studied. Patients with a history of fracture were excluded. At the time of hip and spine dual-energy X-ray absorptiometry (DXA), those willing underwent portable dual-energy X-ray absorptiometry (pDXA) of the wrist. The mean age of the patients was 57 yr. Bone mineral density (BMD) assessment was performed on each patient at four different sites: posterior-anterior lumbar spine, nondominant hip, the distal radius and ulna, and the proximal radius and ulna of the nondominant arm. Comparison of the pDXA results with that of the conventional DXA results showed the highest correlation between pDXA of the distal radius and ulna (DR + U) and the DXA of the femoral neck and lumbar spine. By defining a pDXA (DR + U) T-score 相似文献   

Reproducibility and Concordance in Quantitative Ultrasound Measurements Between Densitometers: A Comparative Study

Although calcaneal quantitative ultrasound (QUS) is an independent predictor of osteoporotic fracture, its role in monitoring changes in bone status remains limited because of its relatively poor precision compared to the rate of bone loss. Recently, imaging QUS has been developed that can standardize the region of interest in the calcaneus with the potential of improving precision. We assessed the concordance and precision of an imaging QUS scanner (UBIS 5000) and a nonimaging scanner (LUNAR Achilles+) in 52 subjects aged between 27 and 79 yr. Each subject had duplicate measurements on each scanner on the same day. The measurements were broad-band ultrasound attenuation (BUA), speed of sound (SOS), and stiffness index, which was derived from BUA and SOS. Precision was evaluated by the standard error of measurement (SEM) and within-subject coefficient of variation (CV). There was significant correlation between the two scanners in all QUS measurements (r > 0.8; p < 0.001); however, BUA and SOS measurements by the UBIS were significantly lower than by the Achilles+. The SEM of BUA (0.6 dB/MHz) and SOS (2.7 m/s) in the UBIS were significantly lower (p < 0.001) than the Achilles+ (1.4 dB/MHz for BUA and 6.3 m/s for SOS). When the SEM was expressed as the percentage of the mean, there were no significant differences in CVs between UBIS (0.9% for BUA and 0.2% for SOS) and Achilles+ (1.2% for BUA and 0.4% for SOS) scanners. The SEM of stiffness index derived by UBIS was not significantly different from that derived by the Achilles+. These data suggest that although there are systematic differences between the UBIS and Achilles+ scanners in QUS measurements, the precision of the two instruments is equivalent.     

Forearm Single X-Ray Absorptiometry in the Identification of Postmenopausal Women With Osteoporosis at the Hip and Spine: A Correlation Study

The International Society for Clinical Densitometry (ISCD) has stated that forearm bone mineral density (BMD) testing combined with a thorough clinical evaluation may be an option for the diagnosis of osteoporosis when central bone density (CBD) testing is not available. This study assessed the performance of two different forearm sites in identifying subjects with spinal and femoral osteoporosis, and defined the 90% sensitivity point for the DTX-100 bone densitometer in the detection of central osteoporosis. Four hundred and two postmenopausal Bulgarian women between the ages of 50 and 81 yr (mean age 60.24 +/- 10.48 yr) participated in this study. Forearm BMD (distal and ultradistal forearm) was measured with a DTX-100 device (Osteometer Meditech, USA) and central BMD (lumbar spine and proximal femur) with a Hologic QDR 4500 A device. Linear T-score correlations among sites, sensitivity and specificity of the forearm site were analyzed. T-score correlations between the forearm and the central sites ranged from 0.32 to 0.69 (p < or = 0.05 for all correlations in age group 50-59). The forearm site sensitivity increased slightly with advancing age, but specificity decreased. When the distal forearm BMD cut point (0.340 g/cm2) was set to achieve 90% sensitivity to identify total hip osteoporosis, specificity was 40%; when the distal forearm BMD cut point (0.410 g/cm2) was set to achieve 90% sensitivity to identify spinal osteoporosis, specificity was 55.4%; when ultradistal forearm BMD cut points (0.280 and 0.320 g/cm2) were set to achieve 90% sensitivity to identify total hip and spinal osteoporosis, specificity was 40.8 and 59.2%, respectively. Forearm bone density measures may be useful to selectively screen for patients with central osteoporosis.     

人工全髋关节置换术对骨质疏松症患者骨密度的影响

目的探讨混合型与生物型人工全髋关节置换术（total hip arthroplasty,THA）对老年骨质疏松症患者骨密度的影响。方法选取老年股骨头无菌性坏死需行THA患者68例,随机分为混合型组与生物型组,每组各34例。混合型组选用混合型假体,Palacos抗生素骨水泥固定股骨柄假体,髋臼假体采用非骨水泥固定;生物型THA组选用Depuy公司人工关节。术后1、3、6、12个月及2年时患者来院复诊测定骨密度（bone densitometry,BMD）,将假体分7个测量兴趣区（region of interest,ROI）。结果两组各测量兴趣区主要数据从术后1个月、术后3个月、术后6个月递减,以术后6个月或术后12个月降至最低,至术后2年又呈现升高趋势;在假体周围,ROI4BMD值最高,ROI7、ROI1BMD值最低。且两组术后BMD变化及趋势,以及各测量兴趣区BMD值比较,均无统计学差异（P〉0．05）。结论混合型与生物型THA术对老年骨质疏松症患者骨密度可能不具有差异性的影响,术后至6个月或12个月内BMD值呈逐渐降低的趋势,2年后又逐渐升高,但骨质疏松性质未发生改变。     

Post-Pregnancy Osteoporosis (PPO): A Case Study

Individuals with back pain during or immediately after pregnancy are suspect for postpregnancy osteoporosis (PPO). These patients are often diagnosed late if at all. This case report was selected to illustrate the presentation of such patients. Common criteria include back pain, spine fractures, occurrence in late pregnancy or within 3 mo postpartum, diagnosis made late, first pregnancy, height loss, lactation, mothers with osteoporosis, low bone density, some recovery of bone mass over years, and pre-existing osteopenia. Previous case reports and literature reviews show similar patient profiles.     

Prospective Identification of Postmenopausal Osteoporotic Women at High Vertebral Fracture Risk by Radiography, Bone Densitometry, Quantitative Ultrasound, and Laboratory Findings: Results From the PIOS Study

Women with established osteoporosis are at high risk to sustain additional vertebral fractures. Treatment may affect the predictive power of bone densitometry and biochemical techniques. There are few prospective studies comparing fracture prediction by dual-energy X-ray absorptiometry (DXA) and other techniques in treated women with established osteoporosis. The objective of this study was to prospectively assess the predictive power of various DXA and quantitative ultrasound (QUS) techniques for identification of women at high risk to develop new fractures over 1-2 yr. Moreover, we wanted to investigate whether previous or ongoing therapy precluded the use of common clinical laboratory blood tests and bone turnover markers for prediction of fracture risk. We measured prevalent fracture status; bone mineral density (BMD) of the whole body, spine, and hip by DXA; QUS of the calcaneus and the patella; hormones and various markers of bone resorption and formation; and took standard blood tests in 124 women (age 64.9 yr +/- 7.9) with manifest and variously treated postmenopausal osteoporosis. Subsequently, new spine fractures were assessed after 1 yr and, in a subset of 87 women, after 2 yr. Prevalent fractures turned out to be the strongest predictor of subsequent vertebral fractures with an age-adjusted odds ratio (OR) of 3.9 per prevalent fracture over 2 yr. Furthermore, our results underline the predictive power of spinal BMD (sOR = 2.1; standardized OR per 1 standard deviation population variance decrease), whole body BMD (sOR: 2.4), and QUS stiffness index of the calcaneus (sOR: 2.8) for vertebral fracture prediction. QUS of the patella did not predict vertebral fractures. Blood sedimentation rate was predictive in the first year (sOR: 1.9). The predictive power of bone turnover markers, however, appeared to be too low to be detectable in a group of this sample size and it may have been reduced because most women were already receiving treatment. In conclusion, radiographic measures, but not the tested laboratory bone turnover markers, enabled us to identify women (from a population of osteoporotic women who have been treated for some time with a variety of medications) who are at highest risk for developing new vertebral fractures within 1-2 yr.     

Determinants of Bone Loss in Elderly Men and Women: A Prospective Population-Based Study

While several studies have described the rate and pattern of involutional bone loss in women, far less information is available for men. Furthermore, the roles of lifestyle and body build in determining bone loss rate in both sexes have been largely extrapolated from cross-sectional studies. We addressed this issue in a population-based longitudinal study which sought to ascertain rates of bone loss at the femoral neck and lumbar spine in a cohort of men and women aged 60–75 years at baseline, and to relate this loss to anthropometric and lifestyle variables. We additionally investigated the capacity of biochemical markers of bone turnover to predict bone loss rates in these subjects. Women lost bone at all sites; this ranged from 0.20%/year at the lumbar spine to 1.43%/year at the femoral trochanteric region. By contrast, men lost only 0.20%/year at the trochanteric region, and gained at the lumbar spine (0.33%/year) and at Ward’s triangle (0.27%/year) over the 4-year period. Anthropometric measurements were associated with bone loss in both sexes; lower baseline body mass index (BMI) and a greater rate of loss of adiposity over the follow-up period were both associated with greater bone loss at all proximal femoral sites. These attained statistical significance after Bonferroni correction at the total proximal femur among both men (r= 0.29), p<0.01) and women (r= 0.31, p<0.05). Lifestyle factors associated with lower rates of bone loss (after adjustment for BMI) included alcohol consumption at the femoral neck among women (p= 0.007) and physical activity at the lumbar spine among men (p = 0.05). Serum parathyroid hormone, 25-hydroxyvitamin D and biochemical markers of bone turnover did not predict bone loss after adjustment for adiposity. Received: 8 December 1998 / Accepted: 8 April 1999     

Immunosuppressant Drugs and Bone Disease: A Clinician''s Perspective

Immunosuppressant agents are used widely for a variety of diseases, and their usage will increase as organ transplantation becomes more frequent. One of the consequences of their administration is the occurrence of rapid bone loss with fractures. Generally, glucocorticoids (GC) are the main culprit, but calmodulin-calcineurin phosphatase inhibitors, e.g., cyclosporine and tacrolimus, seem to play a role as does the underlying disease, which necessitates treatment or organ transplantation. The mechanisms for the bone disease are multifactorial and actively being researched. The management at present is largely empirical and consists of calcium, vitamin D, and antiresorbers, especially bisphosphonates. In order to achieve an optimum treatment strategy, bone density measurements are essential to define the severity of the bone loss, help decide therapy and monitor progress of the patient.     

Assessment of Fracture Risk: Value of Random Population-Based Samples-The Geelong Osteoporosis Study

Fracture risk is determined by bone mineral density (BMD). The T-score, a measure of fracture risk, is the position of an individual's BMD in relation to a reference range. The aim of this study was to determine the magnitude of change in the T-score when different sampling techniques were used to produce the reference range. Reference ranges were derived from three samples, drawn from the same region: (1) an age-stratified population-based random sample, (2) unselected volunteers, and (3) a selected healthy subset of the population-based sample with no diseases or drugs known to affect bone. T-scores were calculated using the three reference ranges for a cohort of women who had sustained a fracture and as a group had a low mean BMD (ages 35-72 yr; n = 484). For most comparisons, the T-scores for the fracture cohort were more negative using the population reference range. The difference in T-scores reached 1.0 SD. The proportion of the fracture cohort classified as having osteoporosis at the spine was 26, 14, and 23% when the population, volunteer, and healthy reference ranges were applied, respectively. The use of inappropriate reference ranges results in substantial changes to T-scores and may lead to inappropriate management.     

Risk Assessment for Osteoporosis Using Bone Mineral Density Determination: A Belgian Perspective

The availability of bone densitometry in daily clinical practice has revolutionized the capacity to detect osteoporosis, to estimate the risk of future fracture, and to select those patients who are likely to benefit most from preventive or therapeutic measures. In spite of the high availability of densitometry in Belgium and the high incidence of risk factors for osteoporosis in elderly women, osteoporosis is presumably underdiagnosed. It is likely that the limited use of widely available technology to evaluate osteoporosis results from a complex interaction of numerous factors, some of which are discussed. In spite of many unanswered questions, the main conclusion to be drawn from the Belgian experience is that a high density of densitometry facilities is no guarantee that the majority of women who are at greatest risk of fracture will actually become the focus of preventive measures or therapy.     

Association of Selective Serotonin Reuptake Inhibitors and Bone Mineral Density in Elderly Women

Depression and osteoporosis are 2 common comorbidities in geriatric patients. There are concerns about the deleterious effects of selective serotonin reuptake inhibitor (SSRI) antidepressant use on bone mineral density (BMD). We examined the association between SSRI use and BMD in elderly women (≥65?yr) referred to a geriatric osteoporosis clinic for bone health evaluation. Cross-sectional analyses using the general linear model were performed on data collected retrospectively from August 2010 to April 2015. A total of 250 women were seen during the study period. Of these, 140 women had complete data on BMD measurements: 22 (15.7%) used an SSRI and 118 (84.3%) did not. The 2 groups, SSRI users and SSRI nonusers, did not differ significantly across any of the covariates tested (age, ethnicity, body mass index, and past and present osteoporosis treatment medications). After adjusting for covariates, there was no difference in the BMDs at the femoral neck (p?=?0.887) or the spine (p?=?0.275) between the 2 groups. Similarly, no difference was seen in the T-scores between SSRI users and nonusers at the femoral neck (p?=?0.924) or at the spine level (p?=?0.393). Our study did not show an association between SSRI use and BMD among elderly women referred for bone health evaluation. Other studies in the literature have been inconclusive, and therefore, robust longitudinal studies are needed to further assess the interaction between SSRI use and predictors of fracture such as BMD, bone turnover markers, and genes involved in bone turnover. Until then, clinicians should closely monitor the bone health of long-term SSRI users.     

青少年脊柱侧凸的普查及其与褪黑素的关系

目的：了解海口市青少年儿童脊柱侧凸患病率及发病机制与褪黑素的关系及作用。方法：应用脊柱侧凸二检法(体检、X线照片)，对8198名7～16岁在校学生进行普查筛选，并按年龄段及性别分组并设对照组，放免法进行褪黑素测定与统计学处理。结果：一检阳性242人，阳性率2．95％；复检阳性17人，占0．21％。其中男性患病率为0．20％。女性患病率为0．21％，男女患病率之比为0．95：1。青春前期10岁前年龄段褪黑素含量均低于青春期组及对照组，尤以女性为显，具有高度统计学意义。结论：学校大范围普查是防治AIS的关键环节。血清中褪黑素含量与AIS发病机制有关。     

The Plated Femur: Relationships Between the Changes in Bone Stresses and Bone Loss

Calculations were made of the alterations in the in vivo cyclic bone stresses due to the application of various plates on the canine femoral shaft. The plate configurations analyzed were those used by previous investigators when studying the influence of plating on bone remodeling. The magnitude of the reduction in the loads borne by the bone tissue and the degree of shift in the bone stress neutral axis during the stance phase of gait was influenced by the geometry of the plate, the plate elastic modulus, and the location of plate application. From a correlation of the calculated alterations in bone stresses with the resulting measured changes in bone mass, it appears that bone remodeling is very sensitive to small changes in cyclic bone stresses. Changes in cyclic bone stresses of 1 MPa (less than 1 percent of the ultimate strength) can cause measurable differences in bone remodeling after a period of a few months.     

Male Osteoporosis Awareness in the Elderly: an Analysis of Dual-Energy X-Ray Absorptiometry Use in Australia Between 1995 and 2015

Osteoporosis is commonly perceived to be a disease confined to aging females, despite ongoing educational interventions. There are few data on the temporal change of dual-energy X-ray absorptiometry (DXA) use in aging males compared to females. Australian Medicare DXA claims between 1995 and 2015 were analyzed to investigate gender differences and temporal change of DXA use in males and females aged 45–85?yr. In females aged 45–54 and 55–64?yr, there was a progressive increase in DXA claims per capita between 1995 until 2002, with little subsequent change from 2002 to 2015 in the younger group, but a slow subsequent increase in females aged 55–64?yr. In males aged 45–54 and 55–64?yr, there was a progressive increase in DXA claims per capita between 1995 and 2002 with an ongoing slow increase from 2002 to 2015. In older females and males aged 65–74, 75–84, or ≥85?yr, there was a progressive increase in DXA claims per capita between 1995 and 2002, with a slow increase thereafter until 2007. After 2007, following the introduction of Medicare eligibility for age over 70, claims per capita increased sharply in all 3 age groups, with a subsequent ongoing increase. The male?:?female claim ratio in all groups demonstrates low relative male DXA use, with the ratio consistently below 1.0. Following the 2007 Medicare change, the male?:?female ratio improved in the 65–74, 75–84, and ≥85 age groups. The rate of increase in the male?:?female ratio in subjects ≥85?yr was significantly greater than that in the 65–74 (p?<?0.001) and 75–84 (p?<?0.001) age groups. DXA use in males is consistently lower than that in females. Government funding intervention appears to have been most effective in relation to very elderly males over 85?yr but less so in relation to the age group 65–84. There is a need for improved education of health professionals about the risk of osteoporosis in males aged 65–84?yr.     

乳腺癌芳香化酶抑制剂治疗期间骨丢失的长期随访结果

目的 评估绝经后激素受体阳性早期乳腺癌患者术后5年芳香化酶抑制剂（aromatase inhibitor,AI）辅助内分泌治疗过程中的骨丢失情况,为骨健康管理提供依据。方法 本研究为前瞻性观察性研究,入组绝经后激素受体阳性早期乳腺癌患者,接受股骨颈、全髋和腰椎L1-L4等部位的双能X线骨密度检测。AI辅助内分泌治疗前进行基线骨密度检查,治疗期间每年检查骨密度1次。分析AI治疗过程中骨密度变化以及骨质疏松发生率。结果 2013年11月至2016年8月共纳入131例患者,中位年龄60岁,中位绝经年龄50岁,AI治疗时间60～100个月。中位随访86个月,AI治疗5年期间患者腰椎、股骨颈、全髋骨密度逐年下降,5年骨密度总下降率分别为6.90%、5.68%、7.14%,其中第1年骨密度下降最快,第2～5年骨密度平稳下降。腰椎骨密度第1年变化率显著高于第2～5年骨密度变化率（P＜0.01）。进一步分层分析显示,基线骨密度、年龄以及体质量指数值未影响患者骨密度下降率。5年间共17例（17%）患者新发骨质疏松,其中15例为基线骨量低下患者,76%出现在腰椎（13/17）,骨折发生率2%（2/100）。结论 绝经后早期乳腺癌患者5年AI辅助内分泌治疗期间骨密度呈持续下降趋势。应加强AI治疗期间的骨健康管理,早期干预减少骨质疏松的发生。     

Influence of High and Low Protein Intakes on Age-Related Bone Loss in Rats Submitted to Adequate or Restricted Energy Conditions

Low energy and protein intake has been suggested to contribute to the increased incidence of osteoporosis in the elderly. The impact of dietary protein on bone health is still a matter of debate. Therefore, we examined the effect of the modulation of protein intake under adequate or deficient energy conditions on bone status in 16-month-old male rats. The animals were randomly allocated to six groups (n = 10/group). Control animals were fed a diet providing either a normal-protein content (13%, C-NP) or a high-protein content (26%) (C-HP). The other groups received a 40% protein/energy-restricted diet (PER-NP and PER-HP) or a normal protein/energy-restricted diet (ER-NP and ER-HP). After 5 months of the experiment, protein intake (13% or 26%) did not modulate calcium retention or bone status in those rats, although a low-grade metabolic acidosis was induced with the HP diet. Both restrictions (PER and ER) decreased femoral bone mineral density and fracture load. Plasma osteocalcin and urinary deoxypyridinoline levels were lowered, suggesting a decrease in bone turnover in the PER and ER groups. Circulating insulin-like growth factor-I levels were also lowered by dietary restrictions, together with calcium retention. Adequate protein intake in the ER condition did not elicit any bone-sparing effect compared to PER rats. In conclusion, both energy and protein deficiencies may contribute to age-related bone loss. This study highlights the importance of sustaining adequate energy and protein provision to preserve skeletal integrity in the elderly.     

Sclerostin Antibody Treatment Increases Bone Formation,Bone Mass,and Bone Strength in a Rat Model of Postmenopausal Osteoporosis

The development of bone‐rebuilding anabolic agents for potential use in the treatment of bone loss conditions, such as osteoporosis, has been a long‐standing goal. Genetic studies in humans and mice have shown that the secreted protein sclerostin is a key negative regulator of bone formation, although the magnitude and extent of sclerostin's role in the control of bone formation in the aging skeleton is still unclear. To study this unexplored area of sclerostin biology and to assess the pharmacologic effects of sclerostin inhibition, we used a cell culture model of bone formation to identify a sclerostin neutralizing monoclonal antibody (Scl‐AbII) for testing in an aged ovariectomized rat model of postmenopausal osteoporosis. Six‐month‐old female rats were ovariectomized and left untreated for 1 yr to allow for significant estrogen deficiency‐induced bone loss, at which point Scl‐AbII was administered for 5 wk. Scl‐AbII treatment in these animals had robust anabolic effects, with marked increases in bone formation on trabecular, periosteal, endocortical, and intracortical surfaces. This not only resulted in complete reversal, at several skeletal sites, of the 1 yr of estrogen deficiency‐induced bone loss, but also further increased bone mass and bone strength to levels greater than those found in non‐ovariectomized control rats. Taken together, these preclinical results establish sclerostin's role as a pivotal negative regulator of bone formation in the aging skeleton and, furthermore, suggest that antibody‐mediated inhibition of sclerostin represents a promising new therapeutic approach for the anabolic treatment of bone‐related disorders, such as postmenopausal osteoporosis.     

Acetabular Fractures in the Elderly: Treatment Recommendations

Acetabular fractures in the elderly population are marked by a high degree of variability in terms of patient and fracture characteristics. Successful outcomes depend on application of highly individualized management principles by experienced teams. Reviewed are indications and outcomes associated with various management options, including closed treatment, open reduction internal fixation, and acute or staged total hip arthroplasty. Proper initial management choices are critical, as early failures and subsequent salvage surgery can be accompanied by significant morbidity. Clinical results after ORIF closely follow the quality of articular reduction and the ability to maintain a congruent reduction of the hip joint. Fracture characteristics predictive of anatomic articular reduction should be treated with ORIF. Fracture characteristics predictive of early post-traumatic arthritis should be treated with simultaneous ORIF and THA. Presented is one referral institution’s treatment algorithm and management approach.The views expressed in this article are those of the author and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the U.S. Government.     

Does Bone Mineral Density and Knowledge Influence Health-Related Behaviors of Elderly Men at Risk for Osteoporosis?

To determine if bone mineral density (BMD) substantially influences health-related behaviors in men at risk for osteoporosis, we surveyed 102 men who were participating in a study of prostate cancer and bone loss. Subjects included 68 men with prostate cancer, 44 of whom were hypogonadal on androgen deprivation therapy, and 34 healthy age-matched controls without prostate cancer. At least 6 mo after an initial evaluation, assessment of BMD, and osteoporosis information session, men were administered a questionnaire regarding their healthrelated behaviors. We found that men with osteopenia were 4 times as likely (13%) and men with osteoporosis were more than 10 times as likely (41%) to start taking bisphosphonates compared to men with a normal bone mass (3%, p < 0.0001). Men with low bone mass were more likely to begin taking calcium (p < 0.05) and vitamin D supplements (p < 0.05). Hypogonadal men were 10 times as likely to begin using bisphosphonates (34%) compared to the control group (3%, p < 0.0001) and twice as likely to begin using calcium supplements (57% vs 24%, p < 0.05). Caffeine consumption, alcohol consumption, dietary calcium intake, exercise, and smoking habits were not different in men with osteoporosis or those who were hypogonadal compared to controls. We conclude that men with low bone mass and hypogonadism were more likely to start using bisphosphonates, calcium supplements, and vitamin D supplements after having a bone density test. However, they were not more likely to make significant health-related lifestyle changes after obtaining the results of their bone mass.